Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer

被引：0
|
作者：
O. Köstek
N. C. Demircan
A. Gökyer
A. Küçükarda
B. S. Sunal
M. B. Hacıoğlu
H. Eslame
S. Solak
E. Yılmaz
S. Uzunoğlu
N. Tunçbilek
İ. Çiçin
B. Erdoğan
机构：
[1] Trakya University School of Medicine,Division of Medical Oncology, Department of Internal Medicine
[2] Trakya University School of Medicine,Department of Radiology
[3] Trakya University School of Medicine,undefined
来源：
Clinical and Translational Oncology | 2019年 / 21卷
关键词：
Skeletal muscle mass; Anti-EGFR treatment; Metastatic colorectal cancer; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1510 / 1517
页数：7
相关论文
共 50 条
  • [31] Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer
    Garcia-Saenz, Jose A.
    Sastre, Javier
    Diaz-Rubio Garcia, Eduardo
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (11): : 737 - 747
  • [32] Doxycycline as preventive treatment of skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy
    Ramirez Daffos, P.
    Jimenez, E.
    Bolanos Naranjo, M.
    Gonzalez-Astorga, B.
    Rubiales, S.
    Ceballos Barbancho, E.
    Rodriguez, J.
    Reina Zoilo, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S117 - S117
  • [33] Anti-EGFR Therapy for Metastatic Colorectal Cancer in the Era of Extended RAS Gene Mutational Analysis
    Elie Kassouf
    Samer Tabchi
    Mustapha Tehfe
    BioDrugs, 2016, 30 : 95 - 104
  • [34] Cetuximab (anti-EGFR) in combination with chemotherapy has no effect on proinflammatory cytokines and markers of T regulatory cells in RAS wild type metastatic colorectal cancer: A study in Algerian patients
    Hayet, Rafa
    Said, Belhadef
    Sarra, Belkhelifa
    Hassan, Mahfouf
    Chafia, Touil-Boukoffa
    ANNALS OF ONCOLOGY, 2017, 28
  • [35] Anti-EGFR Therapy for Metastatic Colorectal Cancer in the Era of Extended RAS Gene Mutational Analysis
    Kassouf, Elie
    Tabchi, Samer
    Tehfe, Mustapha
    BIODRUGS, 2016, 30 (02) : 95 - 104
  • [36] Identifying prognostic subgroups for outcomes in wild-type RAS metastatic colorectal cancer (mCRC) treated with anti-EGFR drugs
    Vladimirova, L.
    Kit, O.
    Abramova, N.
    Storozhakova, A.
    Popova, I.
    Tikhanovskaya, N.
    Ezhova, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [37] Response to "Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer" Reply
    Blauwhoff-Buskermolen, Susanne
    de van der Schueren, Marian A. E.
    Langius, Jacqueline A. E.
    Verheul, Henk M. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) : 3817 - +
  • [38] Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients
    Smith, D.
    Bosacki, C.
    Merrouche, Y.
    BULLETIN DU CANCER, 2009, 96 : S31 - S40
  • [39] Triplet chemotherapy combined with anti-EGFR treatment in RAS wild-type colon cancer: A network meta-analysis
    Di Nardo, Paola
    Giudici, Fabiola
    Basile, Debora
    De Scordilli, Marco
    Torresan, Sara
    Bortolot, Martina
    Rota, Simone
    Foltran, Luisa
    Guardascione, Michela
    Fumagalli, Arianna
    Noto, Claudia
    Guglielmi, Alessandra
    Ongaro, Elena
    Puglisi, Fabio
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma
    Lievre, Astrid
    Ouine, Berengere
    Canet, Jim
    Cartier, Aurelie
    Amar, Yael
    Cacheux, Wulfran
    Mariani, Odette
    Guimbaud, Rosine
    Selves, Janick
    Lecomte, Thierry
    Guyetant, Serge
    Bieche, Ivan
    Berger, Frederique
    de Koning, Leanne
    BRITISH JOURNAL OF CANCER, 2017, 117 (12) : 1819 - 1827
12345